Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data reveals omalizumab prescribing patterns for chronic hives in china

NCT ID NCT07450170

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined how the drug omalizumab is prescribed in real-world practice for adults with chronic urticaria (long-term hives) in China. Researchers analyzed electronic health records from over 3,400 patients to see what doses were commonly used. The goal was to understand treatment patterns, not to test a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3,485 people

The number who actually took part.

Started

Mar 2026

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with chronic urticaria with at least one prescription of omalizumab in the database.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Patients with at least one diagnosis of chronic urticaria during the study period. A chronic urticaria diagnosis is defined as including "chronic urticaria" but without any rule-out terms in the diagnosis name. 2. Patients treated with omalizumab during the identification period. The date of first omalizumab prescription is defined as the index date. 3. Patients aged 18 years or older at index. 4. Patients with at least one medical record ≥12 months prior to index date. Additional inclusion criterion for patients included in healthcare resource utilization (HCRU) outcomes: 5. Patients with at least one medical record ≥12 months post index date. Exclusion criteria: 1. Patients with a diagnosis of allergic asthma during the study period. 2. Patients without any dosing information (raw or derived) for omalizumab.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic urticaria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Inducible Urticaria chronic urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic urticaria

Contacts and locations

Locations

  • Novartis

    Shanghai, 201203, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.